Structural Biology Shared Service

20.0摘要：结构生物学共享服务 结构生物学共享服务（SBSS）协助研究人员收集和解释 结构生物学数据来自三种技术-低温电子显微镜，X射线晶体学， 和核磁共振-作为一种增值手段，以推进癌症生物学研究。SBSS 支持来自马里兰州大学Marlene和Stewart Greenebaum的所有五个研究项目的用户 综合癌症中心（UMGCCC）。SBSS的结构生物学数据帮助研究人员推导出 癌症相关蛋白质和酶的分子作用机制，并允许设计分子 药物，包括分子探针，作为研究和潜在癌症治疗的候选药物。 这三种技术为理解结构和生物分子提供了互补的方法 行动机制。SBSS领导层的专业知识将调查人员引导到适当的结构 生物学方法，将最有效地解决他们的科学问题，然后提供战略， 获得高质量的分析。SBSS被大量使用。例如，18个研究小组使用两个或更多个 结构分析方法SBSS促进早期UMGCCC药物发现与其他合作 UMGCCC共享服务;计算机辅助药物设计中心（CADDC），由MacKerell（MSB）领导; 生物分子治疗中心（Center for Biomolecular Therapeutics，CBT），由Weber（MSB）领导。教师监督 委员会由SBSS用户和外部审查员组成，评估和指导当前的 服务和战略规划。总体而言，SBSS为UMGCCC调查人员提供了最先进的 结构生物学仪器在协作环境中是基于基本结构药物的理想选择 设计研究，以促进高影响力的癌症研究和从实验室到临床的成功。在 2019年SBSS支持了56名研究者的研究，其中40名（71.4%）隶属于UMGCCC。2019年 SBSS为UMGCCC提供了1 790万美元的资金，所有这些资金都经过了同行审查。从2015年到2019年，SBSS 支持了164篇出版物，包括在Science，Cell，PNAS，Nucleic Acids等高影响力期刊上发表的文章 研究，美国化学学会杂志和分子生物学杂志。

20.0 Abstract: Structural Biology Shared Service The Structural Biology Shared Service (SBSS) assists investigators in the collection and interpretation of structural biology data derived from three technologies—cryogenic electron microscopy, X-ray crystallography, and nuclear magnetic resonance—as a value-added means to advance cancer biology research. SBSS supports users from all five research programs at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). The structural biology data from SBSS help investigators derive the molecular mechanisms of action of cancer-related proteins and enzymes and permit the design of molecular agents, including molecular probes as drug candidates for research studies and potential cancer treatments. The three technologies offer complementary approaches to understanding structure and biomolecule mechanisms of action. The expertise of SBSS leadership directs investigators to the appropriate structural biology method(s) that will most efficiently address their scientific questions and then provides strategies for obtaining high-quality analysis. SBSS is heavily used. For example, 18 research groups use two or more structural analysis methods. SBSS facilitates early-stage UMGCCC drug discovery in cooperation with other UMGCCC shared services; the Computer Aided Drug Design Center (CADDC), headed by MacKerell (MSB); and the Center for Biomolecular Therapeutics (CBT), directed by Weber (MSB). The Faculty Oversight Committee, composed of SBSS users and external reviewers, assesses and provides guidance on current services and strategic planning. Overall, SBSS provides UMGCCC investigators with access to state-of-the-art structural biology instrumentation in a collaborative environment that is ideal for basic structure-based drug design research to enable the advancement of high-impact cancer research and bench-to-bedside success. In 2019 SBSS supported studies by 56 investigators, 40 (71.4%) of whom were affiliated with UMGCCC. In 2019 SBSS supported $17.9 million of UMGCCC funding, all of which was peer reviewed. From 2015 to 2019, SBSS supported 164 publications including those in high-impact journals such as Science, Cell, PNAS, Nucleic Acids Research, Journal of the American Chemical Society, and Journal of Molecular Biology.